|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
WO2013186613A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Nasvax Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
JP6498601B2
(ja)
|
2012-07-13 |
2019-04-10 |
ザイムワークス，インコーポレイテッド |
多価ヘテロ多量体足場設計および構築物
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
CA2913370C
(en)
|
2013-05-31 |
2022-12-13 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
HUE048722T2
(hu)
*
|
2013-07-05 |
2020-08-28 |
Genmab As |
Humanizált vagy kiméra CD3 ellenanyagok
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
WO2015109131A2
(en)
*
|
2014-01-15 |
2015-07-23 |
Zymeworks Inc. |
Bi-specific cd3 and cd19 antigen-binding constructs
|
|
KR20230004939A
(ko)
|
2014-02-07 |
2023-01-06 |
맥마스터 유니버시티 |
3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
DK3107938T3
(da)
|
2014-05-28 |
2022-07-11 |
Zymeworks Inc |
Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
|
|
SG11201701627PA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
|
AU2015350075B2
(en)
|
2014-11-17 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using CD3xCD20 bispecific antibody
|
|
UA120286C2
(uk)
*
|
2015-01-08 |
2019-11-11 |
Ґенмаб А/С |
Біспецифічне антитіло проти cd3 і cd20
|
|
US10556952B2
(en)
|
2015-03-30 |
2020-02-11 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to Fc gamma receptors
|
|
ES2754427T3
(es)
*
|
2015-05-13 |
2020-04-17 |
Ablynx Nv |
Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
|
|
MX2017014822A
(es)
|
2015-05-18 |
2018-04-30 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
EP3916018A1
(en)
*
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
ES2957567T3
(es)
|
2015-06-16 |
2024-01-22 |
Hoffmann La Roche |
Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
|
|
WO2017008169A1
(en)
*
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
TWI784917B
(zh)
|
2015-09-23 |
2022-11-21 |
美商再生元醫藥公司 |
最優化抗ｃｄ３雙特異性抗體及其用途
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3913000A1
(en)
*
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
MX2018004515A
(es)
|
2015-10-13 |
2019-04-15 |
Eureka Therapeutics Inc |
Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
|
|
WO2017079272A2
(en)
*
|
2015-11-03 |
2017-05-11 |
Ambrx, Inc. |
Anti-cd3-folate conjugates and their uses
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
KR102463844B1
(ko)
*
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
US11535666B2
(en)
*
|
2016-12-30 |
2022-12-27 |
Cytocares (Shanghai) Inc. |
Trifunctional molecule and application thereof
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
TW201834688A
(zh)
*
|
2017-02-24 |
2018-10-01 |
日商中外製藥股份有限公司 |
藥學組成物、抗原結合分子、治療方法以及篩選方法
|
|
GB201710838D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
EP3661555B1
(en)
*
|
2017-08-01 |
2025-04-16 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
JP7227630B2
(ja)
|
2017-10-12 |
2023-02-22 |
マックマスター ユニバーシティー |
Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
|
|
CN107903324B
(zh)
*
|
2017-11-15 |
2021-01-29 |
北京绿竹生物技术股份有限公司 |
一种结合人cd19和cd3的双特异性抗体
|
|
CN107987169B
(zh)
*
|
2018-01-05 |
2021-10-08 |
阿思科力(苏州)生物科技有限公司 |
一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
IL280875B2
(en)
|
2018-08-31 |
2024-12-01 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
BR112021008486A2
(pt)
*
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
US12463463B2
(en)
*
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2020156405A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel bispecific cd3/cd20 polypeptide complexes
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
CN112390882A
(zh)
*
|
2019-08-19 |
2021-02-23 |
杨洋 |
靶向cd3和cd20的双特异性抗体及其应用
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
EP4110398A4
(en)
*
|
2020-02-27 |
2024-07-10 |
Phanes Therapeutics, Inc. |
ANTIBODIES CONJUGATED WITH FATTY ACID MOLECULES AND THEIR USES
|
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
JP2023541858A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
CN116406293A
(zh)
|
2020-09-10 |
2023-07-07 |
健玛保 |
用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
|
|
JP2023542291A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
CN113735978B
(zh)
*
|
2021-04-22 |
2023-06-30 |
河北森朗生物科技有限公司 |
靶向cd19的嵌合抗原受体、制备方法及其应用
|
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
KR20240037892A
(ko)
|
2021-06-01 |
2024-03-22 |
트리움비라 이뮤놀로직스 유에스에이, 인크. |
클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|